Latest news
Verastem Q2 Earnings Call Highlights - TradingViewTradingView · Fri, 07 Aug 2026 20:04:15 GMTVerastem - Enters Amendment No. 3 To Note Purchase Agreement On August 6, 2026 - SEC Filing - TradingViewTradingView · Fri, 07 Aug 2026 12:58:21 GMTVerastem Amends Oberland Financing, Adding Up to $75 Million Revenue-Share Notes Maturing 2033 - TradingViewTradingView · Fri, 07 Aug 2026 10:13:01 GMTVSTM: Strong Q2 revenue, robust funding, and clinical progress position the business for sustained growth - TradingViewTradingView · Thu, 06 Aug 2026 21:52:35 GMTVSTM: Strong Q2 revenue, enhanced cash, and clinical progress drive positive outlook for 2026 - TradingViewTradingView · Thu, 06 Aug 2026 20:42:28 GMTVSTM: Strong commercial growth and late-stage pipeline drive expansion in RAS/MAPK-driven oncology - TradingViewTradingView · Thu, 06 Aug 2026 20:40:43 GMTVerastem, Inc. Revenue Breakdown – NASDAQ:VSTM - TradingViewTradingView · Fri, 31 Jul 2026 13:25:18 GMT